Application of EGFR (Epidermal Growth Factor Receptor) in urine or urine exosome and polypeptide fragment thereof in type 2 diabetic nephropathy

By detecting EGFR and its polypeptide fragments in urine or urinary exosomes, the challenge of non-invasive diagnosis and disease monitoring of type 2 diabetic nephropathy has been solved. This provides a non-invasive, rapid, and easily repeatable detection method, improving diagnostic efficiency and reducing patient suffering.

CN118897086APending Publication Date: 2024-11-05张曼
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202310492744.9
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2023-05-05
Publication Date
2024-11-05

AI Technical Summary

Technical Problem

Existing technologies cannot provide a non-invasive, convenient, quick, and easily repeatable method for the diagnosis and monitoring of type 2 diabetic nephropathy, and patients need to undergo repeated blood tests over a long period of time, which is inconvenient.

Method used

By utilizing EGFR and its polypeptide fragments in urine or urinary exosomes, and by establishing urinary exosome profiles in healthy individuals, patients with type 2 diabetes without nephropathy, and patients with type 2 diabetic nephropathy, liquid chromatography-mass spectrometry (LC-MS) and data-independent scanning modes are employed to detect EGFR and its polypeptide fragments in urine or urinary exosomes, and to construct formulations for diagnosis, differential diagnosis, disease assessment, treatment efficacy evaluation, and prognosis assessment.

Benefits of technology

It enables non-invasive, rapid, and easily repeatable diagnosis and monitoring of type 2 diabetic nephropathy, improving diagnostic efficiency and reducing patient suffering and examination frequency.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118897086A_ABST
    Figure CN118897086A_ABST
Patent Text Reader

Abstract

The invention provides an application of a urine or urine exosome protein epidermal growth factor (EGFR) and a polypeptide fragment of the EGFR, and particularly relates to an application of the EGFR in urine or urine exosome and the polypeptide fragment of the EGFR in the urine or urine exosome in preparation of preparations for diagnosis, differential diagnosis, illness degree judgment, treatment effect evaluation, monitoring, prognosis evaluation, mechanism research and the like of type 2 diabetic nephropathy. Researches prove that compared with healthy people and type 2 diabetic nephropathy-free patients, the expression of EGFR and polypeptide fragments thereof in urine or urine exosomes in the type 2 diabetic nephropathy patients is increased. The method can be used for various purposes of application detection of patients with type 2 diabetic nephropathy. The advantages of noninvasive acquisition, large-scale repeated sampling and convenient preservation of a urine sample are exerted, and EGFR and polypeptide fragments thereof in urine or urine exosome are detected by utilizing the urine sample.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to new uses of EGFR and polypeptide fragments thereof in urine or urine exosomes, and specifically to the use of EGFR and polypeptide fragments thereof in urine or urine exosomes in preparations for diagnosis, differential diagnosis, disease severity assessment, treatment effect evaluation, monitoring, prognosis assessment and mechanism research of type 2 diabetic nephropathy. Background Art

[0002] Type 2 diabetic nephropathy is a metabolic endocrine disease characterized by glucose and fat metabolism disorders and increased plasma glucose levels, caused by the combined effects of genetic and environmental factors. In recent years, the incidence of type 2 diabetic nephropathy in the global population has increased rapidly, and has become the most challenging global health problem in the 21st century. With the improvement of living standards and changes in lifestyles, the incidence of type 2 diabetic nephropathy in my country has shown a rapid upward trend. Statistics show that the number of type 2 diabetic nephropathy patients in my country currently ranks second in the world, and it is estimated that by 2040, the number of people with type 2 diabetic nephropathy in China will reach 642 million.

[0003] Hyperglycemia in type 2 diabetic nephropathy can lead to metabolic disorders of carbohydrates, proteins, and fats, thereby causing complications in multiple systems such as nerves, kidneys, and cardiovascular diseases, all of which pose a huge hidden danger to public health. The onset of type 2 diabetic nephropathy is relatively hidden, and most patients are not discovered in time, and are often diagnosed only after the clinical manifestations of complications appear. In addition, patients with type 2 diabetic nephropathy have a long course of disease and need long-term or even lifelong blood sugar monitoring. Repeated blood draws and invasive examinations cause many inconveniences to patients. However, if patients with type 2 diabetic nephropathy are not given timely diagnosis and treatment, multiple organ damages often occur throughout the body as the disease progresses, and severe cases may even become disabled or die due to complications. In summary, type 2 diabetic nephropathy not only causes inconvenience and pain to patients, but also brings a heavy burden to patients' families and society. In order to improve the quality of life of patients with type 2 diabetic nephropathy and solve the practical problems of patients, it is extremely necessary to study a non-invasive, convenient, fast, and easy-to-repeat method for type 2 diabetic nephropathy examination.

[0004] EGFR belongs to a family of receptors with tyrosine kinase activity, which consists of four members, including EGFR (ErbB1), ErbB2, ErbB3 and ErbB4. They can be activated by several ligands, including EGF, transforming growth factor-α, amphiregulin, heparin-binding EGF-like growth factor, etc. EGFR is widely expressed in the glomerulus and proximal tubules, and the role of EGFR in the pathogenesis of diabetic nephropathy has been widely studied. In animal models of diabetes and cultured cells treated with high glucose, the phosphorylation level of renal epidermal growth factor is significantly increased. The activation of epidermal growth factor by hyperglycemia leads to multicellular dysfunction, which triggers and accelerates kidney damage. However, inhibition of EGFR can slow the progression of diabetic nephropathy, including improvement of proteinuria and morphological changes. The pathogenesis of EGFR-mediated diabetic nephropathy includes hemodynamic changes, metabolic disorders, inflammatory and immune responses, and renal cell dysfunction.

[0005] Compared with commonly used clinical blood samples, urine can be collected completely non-invasively, continuously, and in large quantities; without homeostatic regulation, it can accumulate more types and larger changes, and many pathological and physiological changes of the body may be reflected in urine. Some relatively small molecular weight protein peptides such as hormones and cytokines will be quickly excreted into urine after entering the blood. The probability of these proteins and peptides being detected in urine is much greater than in blood; before urine is collected, the possible protein degradation process in urine has been completed, so urine protein can remain stable for a long time. Urine usually contains some epithelial cells and blood cells, bacteria, viruses and important exosomes. Since the discovery of urinary exosomes, studies have pointed out that urinary exosomes can be used as a new biomarker reflecting the physiological and pathological physiological state of the human body. More and more studies have shown that exosomes are involved in the pathological and physiological processes related to diabetic nephropathy, which may provide new biomarkers and therapeutic targets for patients with diabetic nephropathy. In order to alleviate the pain of multiple blood draws for patients with type 2 diabetic nephropathy, this experiment, based on previous methodological exploration, hopes to use urine or urine exosome protein or peptide research to achieve painless, convenient, fast and easy-to-repeat urine testing to assist in the diagnosis and disease monitoring of patients with type 2 diabetic nephropathy. Summary of the invention

[0006] The purpose of the present invention is to provide an application of EGFR and its polypeptide fragments in urine or urine exosomes in the preparation of preparations for diagnosis, differential diagnosis, disease severity assessment, treatment effect evaluation, monitoring, prognosis assessment and mechanism research of type 2 diabetic nephropathy.

[0007] Preferably, the amino acid sequence of EGFR in the urine or urine exosomes includes the amino acid sequence shown in SEQ ID NO.1 (1 mrpsgtagaa llallaalcp asraleekkv cqgtsnkltq lgtfedhfls lqrmfnncev 61 vlgnleityv qrnydlsflk tiqevagyvl ialntverip lenlqiirgn myyensyala 121 vlsnydankt glkelpmrnl qgqkcdpscp ngscwgagee ncqkltkiic aqqcsgrcrg 181 kspsdcchnq caagctgpre sdclvcrkfr deatckdtcp plmlynptty qmdvnpegky 241 sfgatcvkkc prnyvvtdhg scvracgads yemeedgvrk ckkcegpcrk vcngigigef 301 kdslsinatn ikhfknctsi sgdlhilpva frgdsfthtp pldpqeldil ktvkeitgfl 361 liqawpenrt dlhafenlei irgrtkqhgq fslavvslni tslglrslke isdgdviisg 421 nknlcyanti nwkklfgtsg qktkiisnrg ensckatgqv chalcspegc wgpeprdcvs 481 crnvsrgrec vdkcnllege prefvensec iqchpeclpq amnitctgrg pdnciqcahy 541 idgphcvktc pagvmgennt lvwkyadagh vchlchpnct ygctgpgleg cptngpkips 601 iatgmvgall lllvvalgig lfmrrrhivr krtlrrllqe relvepltps geapnqallr 661 ilketefkki kvlgsgafgt vykglwipeg ekvkipvaik elreatspka nkeildeayv 721 masvdnphvc rllgicltst vqlitqlmpf gclldyvreh kdnigsqyll nwcvqiakgm 781 nyledrrlvh rdlaarnvlv ktpqhvkitd fglakllgae ekeyhaeggk vpikwmales 841 ilhriythqs dvwsygvtvw elmtfgskpy dgipaseiss ilekgerlpq ppictidvym 901 imvkcwmida dsrpkfreli iefskmardp qrylviqgde rmhlpsptds nfyralmdee 961 dmddvvdade ylipqqgffs spstsrtpll sslsatsnns tvacidrngl qscpikedsf 1021 lqryssdptg altedsiddt flpvpgewlv wkqscsstss thsaaaslqcpsqvlppasp 1081 egetvadlqt q); Or an amino acid sequence derived from the amino acid sequence shown in SEQ ID NO.1 and having the same function as the amino acid sequence shown in SEQ ID NO.1.

[0008] Preferably, the preparation is a kit for detecting EGFR and its polypeptide fragments in urine or urine exosomes of patients with type 2 diabetic nephropathy.

[0009] Preferably, the kit includes an immunological method of antigen-antibody reaction and a kit thereof, such as one or more of aptamer antibodies or antibody fragments that can specifically bind to EGFR and polypeptide fragments thereof.

[0010] Preferably, the detection method includes mass spectrometry and other methods for directly detecting EGFR and its polypeptide fragments and related kits.

[0011] Preferably, the detection method includes methods such as direct detection of EGFR and related nucleic acid detection of its polypeptide fragments and related kits.

[0012] Preferably, the kit further comprises components selected from the following group: any one or a combination of solid phase carrier, diluent, reference substance, standard substance, quality control substance, detection antibody, second antibody, second antibody diluent, luminescent reagent, washing solution, color developing solution and stop solution.

[0013] Preferably, the standard substances include EGFR standard substances and humanized tag antibody standard substances; preferably, the quality control substances include: EGFR quality control substances and humanized tag antibody quality control substances; preferably, the solid phase carrier includes: microparticles, microspheres, glass slides, test strips, plastic beads, liquid chips, microplates or affinity membranes, etc. and other carriers with equivalent functions.

[0014] Preferably, the material of the solid phase carrier is any one of polyvinyl chloride, polystyrene, polyacrylamide, cellulose, and carriers with similar functions.

[0015] The inventors first collected urine specimens from healthy people, patients with type 2 diabetes without nephropathy, and patients with type 2 diabetic nephropathy, extracted urine exosomes according to the standard operating procedures of the Human Urine Proteome Project (HKUPP) and the European Kidney and Urine Proteomics (EuroKUP), identified urine exosomes by transmission electron microscopy, exosome nanoparticle tracking detection, and protein immunoblotting, established urine exosome maps of healthy people, patients with type 2 diabetes without nephropathy, and patients with type 2 diabetic nephropathy by liquid chromatography tandem mass spectrometry (LC-MS / MS), and processed the data by quantitative value correction / calculation of absolute quantitative value, differential analysis, and global clustering analysis of target proteins using data-independent acquisition (DIA) scanning mode. The data obtained from the mass spectrometry of healthy people, type 2 diabetes without nephropathy, and type 2 diabetic nephropathy groups were quantitatively calculated, and finally the differential protein EGFR was obtained.

[0016] The present invention has confirmed through research that compared with healthy people and patients with type 2 diabetes without nephropathy, EGFR and its polypeptide fragments in urine or urine exosomes are highly expressed in patients with type 2 diabetic nephropathy, which is consistent with the clinical diagnosis. Therefore, it is proposed that the detection of EGFR and its polypeptide fragments in urine or urine exosomes can be used for the diagnosis, differential diagnosis, judgment of the severity of the disease, evaluation of the treatment effect, monitoring, prognosis assessment and mechanism research of type 2 diabetic nephropathy.

[0017] The present invention takes advantage of the non-invasive acquisition of urine specimens, large-scale repeated sampling, and convenient storage, and uses urine specimens to detect EGFR and its polypeptide fragments in urine or urine exosomes.

[0018] In order to make the above and other purposes, features and advantages of the present invention more obvious and easy to understand, preferred embodiments are given below and described in detail with reference to the accompanying drawings. BRIEF DESCRIPTION OF THE DRAWINGS

[0019] Figure 1 This is the content of EGFR and its polypeptide fragments in urine or urine exosomes in healthy people, type 2 diabetes without nephropathy, and type 2 diabetic nephropathy groups. (HC-healthy group; T2DN-type 2 diabetes without nephropathy group; DN-type 2 diabetic nephropathy group) Figure 2 It is an analysis of the diagnostic efficacy of EGFR and its polypeptide fragments in urine or urinary exosomes in type 2 diabetic nephropathy. Implementation

[0020] Example 1 Urine specimen collection and processing Healthy people, patients with type 2 diabetes without nephropathy, and patients with type 2 diabetes nephropathy were selected as subjects. Fresh morning urine samples were collected from each group of subjects after admission and placed in a dry, clean container. Exosomes were extracted from concentrated urine samples according to the standard operating procedures of HKUPP and EuroKUP (http: / / www.eurokup.org), resuspended in precooled PBS, and stored in a -80℃ refrigerator. Urinary exosomes were identified by transmission electron microscopy, exosome nanoparticle tracking detection, and protein immunoblotting.

[0021] Example 2 Mass spectrometry analysis of urine exosome peptides The urine samples were subjected to protein extraction and enzymatic desalination, and the extracted protein concentration was measured. The urine exosome protein profiles of the three groups of subjects were constructed using advanced liquid chromatography-mass spectrometry (LC-MS / MS) and data-independent scanning mode (DIA).

[0022] Example 3 Differential peptide data analysis All experiments were performed three times, and all values ​​are expressed as mean ± standard deviation. The analysis results of differentially expressed proteins were obtained by fold change 1.5 times. P A value <0.05 was considered statistically significant, and differentially expressed proteins were screened, and global cluster analysis was performed on the target proteins.

[0023] Example 4 Validation and diagnostic efficacy analysis of EGFR in urine or urinary exosomes Compared with healthy subjects and patients with type 2 diabetes without nephropathy, EGFR in urine or urine exosomes was highly expressed in patients with type 2 diabetic nephropathy. Figure 1 As shown, there is a significant difference in expression.

[0024] Western blot was used to detect EGFR in urine or urine exosomes of healthy people, type 2 diabetic patients without nephropathy, and type 2 diabetic patients with nephropathy. The results were as follows Figure 1 Compared with healthy subjects and patients with type 2 diabetes without kidney disease, EGFR in urine or urinary exosomes was highly expressed in patients with type 2 diabetic kidney disease.

[0025] SPSS 25.0 statistical software was used for ROC curve analysis. The diagnostic efficiency of EGFR and its peptide fragments in urine or urine exosomes in type 2 diabetic nephropathy was evaluated, and the area under the curve (AUC) was 0.842. Figure 2 shown.

[0026] Although the present invention has been disclosed as above with preferred embodiments, it is not intended to limit the present invention. Any person skilled in the art may make some changes and improvements without departing from the spirit and scope of the present invention. Therefore, the protection scope of the present invention shall be subject to the definition of the claims.

Claims

1. The application of EGFR and its polypeptide fragments in urine or urine exosomes in the preparation of preparations for diagnosis, differential diagnosis, disease severity assessment, treatment effect evaluation, monitoring, prognosis assessment and mechanism research of type 2 diabetic nephropathy.

2. The use according to claim 1, characterized in that: The amino acid sequence of EGFR in the urine or urine exosomes is shown in SEQ ID NO.1; The use according to claim 1 is characterized in that the preparation is a kit for detecting EGFR and its polypeptide fragments in urine or urine exosomes of patients with type 2 diabetic nephropathy.

3. The use according to claim 3, characterized in that: The kit includes an immunological method of antigen-antibody reaction and a kit thereof, such as one or more of aptamer antibodies or antibody fragments that can specifically bind to EGFR and its polypeptide fragments.

4. The use according to claim 3, characterized in that: The detection method includes mass spectrometry and other methods for directly detecting EGFR and its polypeptide fragments and related kits.

5. The use according to claim 3, characterized in that: The detection method includes methods such as direct detection of EGFR and its polypeptide fragments or related nucleic acid detection and related kits.

6. The use according to claim 3, characterized in that: The kit also includes components selected from the following group: any one or a combination of solid phase carrier, diluent, reference substance, standard substance, quality control substance, detection antibody, second antibody, second antibody diluent, luminescent reagent, washing solution, color developing solution, and stop solution.

7. The use according to claim 7, characterized in that: The standard products include EGFR standard products and humanized tag antibody standard products; preferably, the quality control products include: EGFR quality control products and humanized tag antibody quality control products; preferably, the solid phase carrier includes: microparticles, microspheres, glass slides, test strips, plastic beads, liquid chips, microplates or affinity membranes, etc. and other carriers with equivalent functions.

8. The use according to claim 8, characterized in that: The material of the solid phase carrier is any one of polyvinyl chloride, polystyrene, polyacrylamide, cellulose and carriers with similar functions.